Concepedia

Wojciech Legieć

WL

Statistics

Publications

14

Citations

1.3K

H-Index

13

Active since

1999

Affiliations

Medical University of Lublin(Current)

Medical University of Silesia

University of Calgary

Lublin Oncology Center

Instituto de Investigación Biomédica de Salamanca

Wojciech Legieć is an author at Medical University of Lublin specializing in medicine, multiple myeloma treatment, and multiple myeloma therapy.

ORCID

Publications per year

1999–2025

14

Publications

14

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

Noopur Raje, Evangelos Terpos, Wolfgang Willenbacher et al. · The Lancet Oncology · 2018 · 441 citations

, , +9

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

María‐Victoria Mateos, Hareth Nahi, Wojciech Legieć et al. · The Lancet Haematology · 2020 · 241 citations · Full text

, , +14

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial

Saad Z. Usmani, Thierry Façon, Vânia Hungria et al. · Nature Medicine · 2025 · 110 citations · Full text

, , +16

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

Mohamad Mohty, Evangelos Terpos, María‐Victoria Mateos et al. · Clinical Lymphoma Myeloma & Leukemia · 2018 · 89 citations · Full text

, , +14

Thalidomide treatment of resistant or relapsed multiple myeloma patients.

Marek Hus, Anna Dmoszyńska, Maria Soroka‐Wojtaszko et al. · PubMed · 2001 · 85 citations · Full text

, , +15

1–5 of 14